Gynergène Caféiné

Gynergène Caféiné is an oral tablet that combines ergotamine tartrate and caffeine, formulated as a prescription medication in the European Union. The product delivers a standard dose of ergotamine tartrate together with caffeine to target acute migraine attacks and associated headache symptoms. As an ergot alkaloid with a central nervous system stimulant, it is intended for patients who need rapid relief from migraine discomfort.

Gynergène Caféiné is indicated for the acute treatment of migraine episodes in adults.

- Alleviation of moderate to severe migraine headache pain, including throbbing or pulsating sensations. - Decrease of accompanying migraine symptoms such as nausea, vomiting, photophobia, and phonophobia. - Shortening of the overall duration of an acute migraine attack when taken at onset. - Option for patients who have not responded to or cannot use triptan medications. - Use as a rescue therapy for breakthrough migraine episodes despite preventive treatment.

The safety profile of Gynergène Caféiné includes both frequent, less severe reactions and rare, potentially serious events.

Common: - Nausea or stomach discomfort. - Dizziness or light‑headed feeling. - Tingling, numbness, or paresthesia in the fingers or toes. - Mild flushing, warmth, or feeling of pressure. - Transient worsening of headache if the medication is not taken promptly.

Serious: - Severe vasoconstriction that may cause chest pain, cardiac ischemia, or peripheral ischemic events. - Allergic reactions including rash, itching, swelling of the face, lips, or tongue, and difficulty breathing. - Persistent vomiting, severe dehydration, or hypertensive crisis requiring medical attention.

Before prescribing Gynergène Caféiné, clinicians should evaluate several precautionary factors to ensure safe use.

- Evaluate cardiovascular disease; ergotamine may worsen coronary, peripheral, or cerebrovascular conditions. - Check for hypertension or uncontrolled high blood pressure. - Use cautiously in patients with liver or kidney impairment. - Avoid during pregnancy or lactation unless benefits clearly outweigh risks. - Do not prescribe to individuals with known ergot allergy or previous ergotism. - Limit frequency to prevent medication‑overuse headache.

Gynergène Caféiné can interact with several medicines; awareness of these interactions helps prevent adverse effects.

Avoid: - Monoamine oxidase inhibitors (MAOIs) – risk of severe hypertension. - Ergot derivatives (e.g., dihydroergotamine) – additive vasoconstriction. - Certain antihypertensives (e.g., beta‑blockers) – may reduce therapeutic effect.

Use with caution: - CYP3A4 inhibitors (e.g., erythromycin, ketoconazole) – may increase ergotamine levels. - CYP3A4 inducers (e.g., rifampin, carbamazepine) – may reduce efficacy. - Other serotonergic agents (e.g., triptans, SSRIs) – potential for serotonin syndrome. - Non‑steroidal anti‑inflammatory drugs (NSAIDs) – may increase risk of gastrointestinal irritation.